Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biota Pharmaceuticals Inc    NABI

SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Operates as an anti-infective drug development company

Aviragen Therapeutics, Inc. engages in the discovery and development of direct-acting antivirals to treat infections.

Its product candidates include vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; BTA074, a topical antiviral treatment for genital warts caused by human papillomavirus types 6 & 11; BTA585, an oral fusion protein inhibitor for the treatment of RSV-A and RSV-B infections; and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections.

The company was founded on November 8, 2012 and is headquartered in Alpharetta, GA.
Managers
NameAgeSinceTitle
Joseph M. Patti, PhD532012President, CEO & Executive Director
Russell H. Plumb MBA, CPA582012Executive Chairman
Mark P. Colonnese, MBA612015Chief Financial Officer & Executive Vice President
Anna Novotney-Barry-2013Vice President-Clinical Development
John H. Vernachio, PhD-2014Vice President-Preclinical Development
Geoffrey F. Cox, PhD732012Independent Non-Executive Director
Anne M. VanLent692013Lead Independent Non-Executive Director
Michael R. Dougherty592013Independent Non-Executive Director
John P. Richard, MBA592013Independent Non-Executive Director
Armando Anido, MBA592015Independent Non-Executive Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 38,649,237 38,192,309 98.8% 0 0.0% 98.8%
Shareholders
NameEquities%
Broadfin Capital LLC 3,179,226 8.23%
East Hill Management Co. LLC 3,068,358 7.94%
Krensavage Asset Management LLC 2,836,326 7.34%
SC Fund Management LLC 1,972,632 5.10%
Renaissance Technologies LLC 1,058,103 2.74%
Fidelity Management & Research Co. 1,005,345 2.60%
The Vanguard Group, Inc. 997,897 2.58%
BlackRock Fund Advisors 474,756 1.23%
Landon Thomas Clay 413,259 1.07%
Stonepine Capital Management LLC 314,421 0.81%
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
BIOTA PHARMACEUTICALS INC23
AMGEN16.30%125 059
CELGENE CORPORATION13.40%102 691
GILEAD SCIENCES2.43%95 790
REGENERON PHARMACEUTICALS28.73%50 205
VERTEX PHARMACEUTICALS107.30%38 163
ACTELION24.26%30 756
GENMAB15.94%13 225
EXELIXIS, INC.79.61%7 871
KITE PHARMA INC182.78%7 324
BIOVERATIV INC0.00%6 186
TESARO INC-15.23%6 122
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.-16.92%4 727
NEUROCRINE BIOSCIENCES, INC.39.64%4 724
BLUEBIRD BIO INC57.29%4 427
HUALAN BIOLOGICAL ENGINEERING INC--.--%4 029
PEPTIDREAM INC-42.35%3 642
CLOVIS ONCOLOGY INC61.57%3 508
BIOCON LTD10.68%3 074
AVEXIS INC95.60%2 981
BEIGENE LTD (ADR)130.63%2 967
Company contact information
Aviragen Therapeutics, Inc.
2500 Northwinds Parkway
Suite 100
Alpharetta, GA 30009

Phone : +1.678.221.3343
Web : www.aviragen.com
© 2017 People , Fundamentals and Ownership